阿达木单抗在克罗恩病合并症状性小肠狭窄患者中的疗效:多中心、前瞻性、观察性队列(CREOLE)研究
该多中心前瞻性观察性队列纳入97例克罗恩病合并症状性小肠狭窄患者,基线行磁共振小肠造影后接受阿达木单抗治疗。第24周64%(62/97)患者治疗成功,预后评分将患者分为良好、中等和不良预后组,成功率分别为43/49、17/28和1/16;中位随访3.8年后,第24周成功者中45.7%±6.6%维持长期成功,全队列50.7%±5.3%在4年内未接受肠切除。
要点
- 阿达木单抗治疗克罗恩病合并症状性小肠狭窄,第24周64%(62/97)患者治疗成功。
- 预后评分良好组成功43/49,中等组17/28,不良组1/16。
- 中位随访3.8年,第24周成功者中45.7%±6.6%在4年时仍维持长期成功。
核心结论
- 克罗恩病合并症状性小肠狭窄患者中约三分之二对阿达木单抗治疗有成功应答,且近半数成功应答者的疗效维持至随访结束;超过半数患者在开始治疗后4年免于手术。
研究设计与样本
- 多中心、前瞻性、观察性队列研究,2010年1月至2011年12月筛查105例,纳入97例克罗恩病合并症状性小肠狭窄患者,基线行磁共振小肠造影后接受阿达木单抗治疗。
主要发现
- 第24周62/97(64%)患者达到治疗成功。
- 预后评分良好组成功43/49,中等预后组17/28,不良预后组1/16。
- 中位随访3.8年,第24周成功者中45.7%±6.6%(即全队列的29%)在4年时仍维持长期成功。
- 全队列中50.7%±5.3%的患者在纳入后4年未接受肠切除。
关键数值与推荐
- 主要终点为第24周治疗成功,定义为继续阿达木单抗治疗且未使用禁止的治疗(纳入后8周后使用糖皮质激素、其他抗TNF药物)、未行内镜下扩张或肠切除。
- 预后评分基于基线因素独立关联分析构建,将患者分为良好、中等和不良预后组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The efficacy of anti-tumour necrosis factors (anti-TNFs) in patients with Crohn's disease (CD) and symptomatic small bowel stricture (SSBS) is controversial. The aim of this study was to estimate the efficacy of adalimumab in these patients and to identify the factors predicting success. DESIGN: We performed a multicentre, prospective, observational cohort study in patients with CD and SSBS. The included patients underwent magnetic resonance enterography at baseline and subsequently received adalimumab. The primary endpoint was success at week 24, defined as adalimumab continuation without prohibited treatment (corticosteroids after the eight week following inclusion, other anti-TNFs), endoscopic dilation or bowel resection. The baseline factors independently associated with success were identified using a logistic regression model, leading to a simple prognostic score. Secondary endpoints were prolonged success after week 24 (still on adalimumab, without dilation nor surgery) and time to bowel resection in the whole cohort. RESULTS: From January 2010 to December 2011, 105 patients were screened and 97 were included. At week 24, 62/97 (64%) patients had achieved success. The prognostic score defined a good prognosis group with 43/49 successes, an intermediate prognosis group with 17/28 successes and a poor prognosis group with 1/16 successes. After a median follow-up time of 3.8 years, 45.7%±6.6% (proportion±SE) of patients who were in success at week 24 (ie, 29% of the whole cohort) were still in prolonged success at 4 years. Among the whole cohort, 50.7%±5.3% of patients did not undergo bowel resection 4 years after inclusion. CONCLUSIONS: A successful response to adalimumab was observed in about two-thirds of CD patients with SSBS and was prolonged in nearly half of them till the end of follow-up. More than half of the patients were free of surgery 4 years after treatment initiation. CLINICAL TRIAL REGISTRATION NUMBER: NCT01183403; Results.
引用
- Bouhnik Y, Carbonnel F, Laharie D, et al. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2017. PMID: 28119352. doi:10.1136/gutjnl-2016-312581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。